PFO Closure After Thromboembolism Linked to Strong 20-Year Outcomes
A new 20‑year follow‑up of 130 patients who received transcatheter patent foramen ovale (PFO) closure after a paradoxical embolism shows sustained safety and efficacy. The cohort, with a mean age of 46, experienced a recurrent stroke rate of 0.04 per 100 patients per year and a TIA rate of 0.25 per 100 patients per year. Bleeding complications occurred in 13% of patients, predominantly among women on antithrombotic therapy. Most procedures used Abbott’s Amplatzer PFO occluder, and the study underscores the durability of the intervention over two decades.
Iron Nanoparticle Eliminates Tuberculosis in Mice and May Pave the Way for New Treatments
Brazilian researchers have shown that an iron‑based compound, ferroin, encapsulated in lipid nanoparticles, completely eradicated Mycobacterium tuberculosis from mouse lungs after a 30‑day course. The formulation, LNP@FEP, stabilizes the drug, enhances the activity of existing antibiotics, and targets bacterial cell‑wall synthesis....
Zimmer Biomet Says Its SynTuition Algorithm Enhances Diagnostic Certainty
Zimmer Biomet announced that its machine‑learning tool SynTuition dramatically improves diagnostic certainty for periprosthetic joint infection (PJI). In a study of 274 real‑world cases, the algorithm matched expert diagnoses 96% of the time, outpacing a pooled physician group that achieved...
Soft-Robotic Glove Uses 37 Actuators to Cut Hand Swelling by up to 25%
Cornell researchers unveiled EdemaFlex, a soft‑robotic glove equipped with 37 shape‑memory‑alloy actuators that apply sequential pressure across all five fingers and the palm. In a small home‑use study of seven edema patients, a single 30‑minute session reduced hand volume by...
Housecall Providers to Affiliate With Chapters Health System
Oregon‑based Housecall Providers has signed a definitive agreement to affiliate with Chapters Health System, extending the nonprofit’s footprint in the Pacific Northwest. The transaction is slated to close in late spring or early summer 2026, subject to regulatory clearance. The...
Withdrawn | Non-Malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
The FDA has removed several accelerated approvals for non‑malignant hematological, neurological, and other disorder indications after post‑marketing requirements were withdrawn. These withdrawn indications are not reflected in official listings until a Federal Register notice or label update is issued. The...
Ongoing | Non-Malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
The FDA’s ongoing accelerated‑approval list details 30+ drugs for non‑malignant hematologic, neurologic and other rare disorders that remain contingent on post‑marketing requirements (PMRs). Each entry cites the indication, approval date, specific confirmatory trial design, and a projected completion date ranging...
Accelerated Approval Program
The FDA’s Accelerated Approval Program permits earlier market entry for drugs treating serious conditions by relying on surrogate endpoints that predict clinical benefit. Companies must later complete confirmatory trials; positive results convert the approval to traditional status, while negative outcomes...
Drive Strategic Growth with Smarter Workforce Planning
U.S. hospitals are pairing enterprise resource planning (ERP) systems with AI‑powered human capital management (HCM) platforms to tighten workforce planning as clinical services expand. Leaders at Johns Hopkins, Henry Ford and Rush describe multi‑year integrations that promise real‑time staffing visibility,...
FDA Shares New Warning About Johnson & Johnson Heart Pumps After 4 Injuries
The FDA issued an early‑alert notice on February 3, 2026, highlighting a leak risk in Generation 1 purge cassettes used with Johnson & Johnson MedTech’s Impella RP heart‑pump sets. A leak can trigger a low‑pressure alarm, potentially causing biomaterial ingress, pump stoppage, and loss...
Baba Emerges From Stealth with $6.5M to Launch Medicare Advocacy Platform
Baba, a patient‑advocacy startup for seniors, announced its emergence from stealth with a $6.5 million seed round led by General Catalyst. The platform blends dedicated nurses and social‑workers with an AI companion to resolve insurance denials, scheduling gaps, and other operational...
![[Comment] Managing Complex Antiretroviral Regimens](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/b8eed98261dfc36d8f4d646ed514fe50.webp)
[Comment] Managing Complex Antiretroviral Regimens
Switching antiretroviral therapy (ART) in people with HIV who have achieved sustained virological suppression is now a routine part of modern care. Advances in drug formulation, tolerability, and the rise of single‑tablet regimens have expanded treatment objectives beyond viral control....
STAT+: A Rare Disease Drug Was Approvable, Then It Wasn’t. Inside a Surprise Rejection by the FDA
An experimental cell therapy for a rare post‑transplant blood cancer, developed by Atara Biotherapeutics and Pierre Fabre, was initially deemed approvable by FDA reviewers but was abruptly rejected in February 2026 over alleged clinical data deficiencies. The disease affects roughly...
How AI Is Transforming Dermatology Care in Austin
Artificial intelligence is now embedded in Austin dermatology clinics, where AI‑driven imaging tools assist physicians in diagnosing skin lesions, classifying conditions, and tracking treatment progress. Studies show deep‑learning models can match dermatologist accuracy for skin‑cancer detection, offering a secondary safety...
ViVE 2026: Change Management Is Key in Clinical Adoption of AI
At ViVE 2026, Tampa General Hospital highlighted that change management, not technology, is the primary barrier to clinical AI adoption among nurses. The hospital detailed its partnership with Microsoft to deploy an AI assistant that automatically populates custom nursing flow...
Q&A: Nemours Children’s Health Expands Pediatric Care at Home
Nemours Children’s Health launched the Advanced Care at Home program, a virtual, technology‑enabled service that lets medically stable pediatric patients recover at home while receiving 24/7 clinical support. The model leverages Epic MyChart and a centralized command center to deliver...
Bridging the Translation Gap for Regenerative Tissues
Muvon Therapeutics, a clinical‑stage company developing regenerative muscle treatments, is confronting the translation gap between academic discovery and commercial manufacturing. The firm highlights three core hurdles: co‑developing evolving regulatory frameworks, automating novel manufacturing processes, and recruiting personnel with GMP expertise....
Samsung Joins CEPI Vaccine Network to Prepare for Next Pandemic
Samsung Biologics has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network, committing to develop a ready‑to‑activate recombinant protein vaccine platform. Backed by a $20 million budget, Samsung will pre‑agree manufacturing processes, run simulated outbreak drills, and prepare...
United Unveils Newly Partnered Soft Mist Inhaler; Mannkind Sinks
United Therapeutics announced a partnership to launch a soft‑mist inhaler, targeting more efficient pulmonary drug delivery for its pipeline. The collaboration marks a strategic pivot away from traditional propellant‑based devices and positions United in the growing soft‑mist market. Investors reacted...
Alkermes’ Richard Pops to Step Down After Three-Decade Run as CEO
Richard Pops will step down as Alkermes CEO on July 31 after a 32‑year tenure, remaining as board chair. COO Blair Jackson will succeed him and join the board during the transition. Under Pops, Alkermes shifted from drug‑delivery to commercial...
Just Two Days of Oatmeal Cut Bad Cholesterol by 10%
A University of Bonn randomized trial published in Nature Communications found that a two‑day, calorie‑restricted diet consisting of 300 g of oatmeal per day reduced LDL cholesterol by about 10 percent in participants with metabolic syndrome. The oat‑rich group also lost roughly...
Music Beats Cancer Aims to Bring Everyone to the Stage
Music Beats Cancer, a nonprofit founded by former cancer researcher Mona Jhaveri, uses live music and a peer‑to‑peer platform to funnel public donations directly to early‑stage biotech firms tackling cancer. By turning song likes into dollars, the organization bridges the...
New Insights Into Hypertension and MACE Reduction in HIV: Steven Grinspoon, MD
A recent analysis of the REPRIEVE randomized trial shows that pitavastatin reduces incident hypertension by 17 % and cuts major adverse cardiovascular events (MACE) by 36 % in adults living with HIV. The findings extend statins’ benefit beyond LDL‑cholesterol lowering, highlighting a...
Colo. FD Launches Community Paramedic Program to Curb Repeat 911 Calls
The Grand Junction Fire Department has launched a Community Paramedic Program aimed at curbing repeat 911 calls by providing in‑home follow‑up for high‑utilization patients with chronic illnesses. Designated paramedics will visit residents within 24‑48 hours of an emergency call to...
Legionella Learnings: What the NY Outbreak Signals About a Growing National Vulnerability
The August 2025 New York Legionella outbreak was linked to contaminated cooling‑tower water across multiple buildings, exposing systemic infrastructure flaws. Traditional laboratory culturing can take up to ten days, allowing the bacteria to proliferate and spread. New rapid on‑site testing...
FDA Clears PCR Test that Detects 11 Gastrointestinal Pathogens
The FDA has cleared Cepheid’s Xpert GI Panel, a multiplex PCR test that identifies 11 gastrointestinal pathogens—including eight bacteria, two parasites and one virus—from a single stool sample. Results are available in just over an hour, dramatically faster than traditional culture...
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
The FDA’s Center for Drug Evaluation and Research has launched the Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D) initiative under its Accelerating Rare disease Cures (ARC) program. LEADER 3D provides a suite of educational videos, downloadable...
How $50 Billion Can Help Transform Rural Healthcare
CMS has launched a $50 billion Rural Health Transformation Program aimed at overhauling care delivery in underserved areas. Founder Michael Dalton of Ovatient argues the initiative will only succeed if the funding fuels new value‑based, virtual‑first models that leverage telehealth and...
Antibacterial Effects of Crude Extracts From Tithonia Diversifolia and Solanum Torvum on Selected Shigella Species Demonstrated In Vitro
Researchers evaluated crude extracts from the African weed Tithonia diversifolia and the nightshade Solanum torvum for antibacterial activity against several Shigella strains. In vitro assays demonstrated clear zones of inhibition, with minimum inhibitory concentrations between 125 µg/mL and 250 µg/mL. Both extracts...
Engineered Nanoplatform with Dual Anti‐Inflammatory and Microbiota‐Modulating Actions for Targeted Therapy in Chronic Inflammatory Bowel Disease
The study introduces BG/SOD@ZIF‑zc, a multifunctional nanoplatform that encapsulates superoxide dismutase within a copper‑doped ZIF framework and coats it with bacterial ghosts for targeted delivery to the colon. The formulation retains SOD activity in the harsh gastrointestinal tract, efficiently scavenges...
Male Infertility Care to Shift Treatment Burden From Women
Infertility has long been framed as a women's issue, yet about half of cases stem from male factors. New treatments such as Igyxos' IGX12 monoclonal antibody, which enhances follicle‑stimulating hormone activity, aim to improve sperm production and reduce the physical...
Millions Are Overdue For Colon Cancer Screening
The death of 48‑year‑old actor James Van Der Beek underscores a surge in colorectal cancer among adults under 50, prompting the U.S. Preventive Services Task Force to lower the screening start age to 45 in 2021. A 2024 report estimates that roughly...
Division of Applied Regulatory Science
The Division of Applied Regulatory Science (DARS) operates within the FDA’s Office of Clinical Pharmacology and the Office of Translational Sciences. Its mandate is to translate emerging scientific advances into the agency’s regulatory framework, tackling complex questions that hinder drug...
Valo Health CEO: We Don’t Want Investors To Drive the Science
Valo Health is reshaping drug development by applying AI to human causal biology, aiming to raise clinical success rates from roughly 10% to 20%. The company leverages over 17 million de‑identified patient records and Mendelian randomization to pinpoint genetically validated targets....
Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills
Novo Nordisk has struck a deal with Boston biotech Vivtex worth up to $2.1 billion to develop next‑generation oral GLP‑1 obesity and diabetes pills. The partnership leverages Vivtex’s AI‑driven gastrointestinal‑on‑a‑chip platform that can boost drug absorption by orders of magnitude. Novo...
China’s Biopharma Advance Draws Financial Investment
Chinese biotech firms are moving beyond licensing deals as capital markets open, highlighted by a 64% rise in the Hang Seng Biotech Index in 2025. Reforms to listing rules since 2018 have unlocked public financing, enabling a record $138 billion in...
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
A patient in MacroGenics' Phase 2 LINNET trial of the bispecific antibody lorigerlimab suffered grade 4 neutropenia and septic shock, leading to a fatality and prompting the FDA to place a partial clinical hold on the study. The company also reported three...
Proven Ways UKG Pro WFM Can Improve Healthcare Scheduling
UKG Pro Workforce Management (WFM) offers a structured, data‑driven approach to healthcare scheduling, tackling the sector’s chronic staffing volatility. By enabling early offers of open shifts through advanced scheduling, organizations can pre‑empt gaps, lower overtime, and align skill sets with patient...
How This Startup Is Showing that Voice-First AI Can Scale in Clinical Care for Root Cause Analysis
O-Health, an 18‑month‑old clinical AI startup, has built a voice‑first operating system that turns doctor‑patient conversations into structured clinical intelligence in real time. The platform runs on an edge‑first, sovereign AI stack with in‑house medical ASR and small language models,...
Translating Single-Cell Research Into Routine Preventive Screenings
Researchers are exploring single‑cell omics as a next‑generation tool for preventive health screening. By profiling thousands of individual cells, the technology can detect subtle genetic mutations and immune‑cell shifts years before clinical symptoms appear. Early studies have identified driver mutations...
COVID-19: Federal Efforts to Support Behavioral Health Programs During the Pandemic
The Substance Abuse and Mental Health Services Administration (SAMHSA) led a massive federal response to keep behavioral health services operational during COVID‑19, awarding over $32 billion in grants from FY2020‑2023, including $8.3 billion in pandemic‑specific funding. SAMHRA provided grant extensions, telehealth prescribing...
Zifo and Maze Therapeutics Partner to Power Precision Medicine
Zifo and Maze Therapeutics have teamed up to launch an AI‑powered platform that manages, stores, and scales massive biobank datasets. The solution tackles the fragmentation of genetic, proteomic, and phenotypic data by providing a unified workflow that delivers summary statistics...
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Eli Lilly’s obesity drug Zepbound achieved a 25.5% weight loss in a head‑to‑head Phase 3 trial, outpacing Novo Nordisk’s CagriSema and sending Novo’s shares down 20%. The FDA launched Rare Disease Week, issuing draft guidance for a new Plausible Mechanism Pathway that...
National Safety Council Launches SIF Prevention Tool that Clinical Laboratories Can Use
The National Safety Council introduced the Organization Safety Gap Analysis Tool, a digital assessment that translates its evidence‑based SIF Prevention Model for clinical laboratories. The ten‑to‑fifteen‑minute, color‑coded questionnaire evaluates seven core safety elements, from leadership to continuous improvement. By highlighting...
SteinCares Forges Licensing Agreement with Shilpa Biologicals for Biosimilars Across Latin America
SteinCares has signed a strategic licensing agreement with Shilpa Biologicals to commercialize a biosimilar across Latin America. Under the deal, SteinCares receives exclusive rights to register, market and distribute the product throughout the region, while Shilpa Biologicals will complete development...
Stryker Unveils Synchfix EVT for Flexible Syndesmotic Ankle Fixation
Medical device maker Stryker has launched Synchfix EVT, a flexible syndesmotic fixation system designed to simplify ankle stabilization procedures. The all‑in‑one, single‑use device integrates suture tensioning handles and a low‑profile titanium medial implant, reducing procedural complexity for both adult and adolescent...
Vico Therapeutics Initiates Patient Dosing for VO659 Phase I/IIa Trial
Vico Therapeutics has initiated patient dosing in an expanded European cohort for its Phase I/IIa VO659 trial, targeting Huntington's disease, spinocerebellar ataxia type 3 and type 1. The study employs a twice‑annual intrathecal regimen and will monitor safety, tolerability, pharmacodynamics and pharmacokinetics...
NorthX Biologics and Demeetra Collaborate on GMP Manufacturing and CLD
NorthX Biologics and Demeetra have formed a strategic alliance to provide an end‑to‑end solution that couples Demeetra’s CleanCut CHO cell line development platform with NorthX’s GMP manufacturing capabilities. The partnership leverages a high‑titre GS‑knockout CHO cell line that carries no...
Evolution Summit By Marcus Evans | May 7-8, 2026 | The Ritz-Carlton, Fort Lauderdale, Florida
The Evolution Summit, organized by Marcus Evans, will take place May 7‑8, 2026 at the Ritz‑Carlton in Fort Lauderdale. The invitation‑only event convenes senior clinical‑trial executives with innovative suppliers to discuss pressing challenges in clinical operations and drug development. Featured speakers include...
Labcorp Expands PathAI Pact to Roll Out Digital Pathology Platform in US
Labcorp announced an expanded partnership with PathAI to deploy the AISight Dx digital pathology platform across its U.S. anatomic pathology labs and hospital sites. The AI‑enabled software will allow pathologists to scan, annotate and diagnose slides digitally, aiming to cut turnaround...